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ABSTRACT 
 
Background: Patients at-risk of severe exacerbations contribute disproportionally to asthma 
mortality, morbidity and costs. We evaluated the effectiveness and costs of using “asthma risk 
registers” for these patients in primary care.  
Methods: In a cluster-randomised trial, 29 primary care practices identified 911 at-risk asthma 
patients using British asthma guideline criteria (severe asthma plus adverse psychosocial 
characteristics). Intervention practices added electronic alerts to identified patients’ records to flag 
their at-risk status and received practice-based training about using the alerts to improve patient 
access and opportunistic management. Control practices continued routine care. Numbers of 
patients experiencing the primary outcome of a moderate-severe exacerbation (resulting in death, 
hospitalisation, accident and emergency (A&E) attendance, out-of-hours contact, or a course/boost 
in oral prednisolone for asthma), other healthcare and medication usage, and costs over one year 
were derived from practice-based records.  
Results: There was no significant effect on exacerbations (control: 46·5%; intervention: 53·6%, 
odds ratio (OR), 95% confidence interval = 1·30, 0·93-1·80). However, this composite outcome 
masked relative reductions in intervention patients experiencing hospitalisations (OR 0·50, 0·26-
0·94), A&E (OR 0·74, 0·42-1·31) and out-of-hours contacts (OR 0·79, 0·45-1·37); and a relative 
increase in prednisolone prescription for exacerbations (OR 1·31, 0·92-1·85). Furthermore, 
prescription of nebulised short-acting β-agonists reduced and long-acting β-agonists increased for 
intervention relative to control patients. The adjusted mean per patient healthcare cost was £138·21 
lower (p=0·837) amongst intervention practices.  
Conclusion: Using asthma risk registers in primary care did not reduce treated exacerbations, but 
reduced hospitalisations and increased prescriptions of recommended preventative therapies without 
increasing costs.  
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What is the key question? 
 
Does implementing “asthma risk registers” to flag the status of at-risk asthma patients in primary 
care, and providing training to practice staff on their use to facilitate access and opportunistic 
asthma management, reduce the number of at-risk patients experiencing moderate-severe 
exacerbations, improve aspects of care and reduce associated healthcare costs?  
 
What is the bottom line? 
 
Using asthma risk registers in primary care did not reduce overall exacerbations. However, this 
composite outcome appeared to mask reductions in crisis events including hospitalisations 
alongside improvements in care reflected in increased prescriptions of recommended preventative 
therapies, without increasing overall healthcare costs. 
 
Why read on?  
 
Use of “asthma risk registers” is mentioned in British asthma guidelines, and this study is the first 
to detail how they can be implemented and provide reliable, generalisable evidence on their 
potential benefit.  
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INTRODUCTION 
 
Despite effective treatments and management guidelines,[1] many asthma patients experience 
inadequate disease control, with asthma causing 1% of disability-adjusted life-years lost and 1 in 
250 deaths worldwide.[2] Each year, 25% of asthma patients in Western Europe require 
unscheduled healthcare, and 7% are hospitalised, for asthma.[3]. Total annual societal costs of 
asthma are estimated at $56 billion[4] and £2·5 billion[2] in the US and UK respectively. Estimated 
costs of treating patients experiencing exacerbations are 3·5 times those of treating well-controlled 
asthma[5] with unscheduled care accounting for over two-thirds of costs in those with poorly-
controlled disease.[6]  
 
Epidemiological studies[7,8] suggest that the majority of patients at-risk of severe exacerbations are 
potentially identifiable. They characteristically have severe asthma plus poorly controlled disease, 
commonly resulting from poor adherence or other psychosocial problems.[1] However, due to 
complicating clinical and psychosocial characteristics, these patients are often excluded from 
studies of, or fail to attend,[9] educational initiatives that improve outcomes in general asthma 
populations.[10] Existing evidence is thus unlikely to be generalisable to this group. Furthermore, 
there is a paucity of high-quality studies of non-pharmacological interventions specifically targeting 
patients with severe asthma, particularly in primary care.[11] 
 
Although at-risk patients under-use primary care services and often fail to attend scheduled 
appointments,[12] opportunistic asthma management and earlier emergency treatment might be 
facilitated if they are identified at each healthcare contact. Our pilot study using an “asthma risk 
register” to alert staff to the status of at-risk asthma patients in a single primary care practice 
suggested it was a low-cost intervention that reduced emergency treatments and service use to 
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levels of matched controls.[13] Use of risk registers is mentioned in British asthma guidelines,[1] 
but they are not included in UK quality measures for primary care[14] due to lack of evidence. The 
aim of this study, conducted as a cluster-trial given the practice-level intervention, was therefore to 
evaluate whether, compared to routine care, use of asthma risk registers reduced numbers of at-risk 
patients experiencing exacerbations, improved aspects of care and altered associated healthcare 
costs. 
 
 
METHODS 
 
Design and participants 
 
A pragmatic cluster-randomised trial in which data collected spanned the period November 2006 – 
May 2009 was conducted in interested primary care practices in Norfolk, UK meeting the eligibility 
criteria of: 1) having a computer system that supported addition of electronic alerts to patient 
records; and 2) not already using an electronic system to support targeted, prospective management 
of selected at-risk asthma patients (Figure 1). Clinicians at practices identified at-risk asthma 
patients aged 5+ years in two stages using British guideline criteria[1] (Figure 2). A database 
manager then randomised practices using a computer-generated list of random permutations with a 
block size of two and stratified according to whether their  Index of Multiple Deprivation (IMD) 
score was above or below the Norfolk median.[15] Practices in a block were randomised 
simultaneously to ensure allocation concealment. 
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Figure 1: CONSORT diagram showing flow of practices (N) and patients (n) through the study 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Survey sent to local GP practices, N=113 
Randomised to intervention 
group, N=15 (n=514) 
Randomised to control group, 
N=15 (n=455) 
Eligible & agreed to participate N=33 
Severe asthma patients identified via search, N=30 (n=2049) 
At-risk asthma patients selected by clinician, N=30 (n=973) 
Baseline data available and 
included in ITT analysis, 
N=14 (n=457, n=2 incomplete 
data due to joining practice) 
Excluded as software 
change meant alert not 
possible, N=1 (n=48)  
Baseline data available and 
included in ITT analysis, 
N=15 (n=454, n=4 incomplete 
data due to joining practice) 
Patients not deemed 
at-risk (n=1099) 
At-risk patients added by 
clinician (n=23) 
Not recruited as 
required sample size 
exceeded, N=3 
9 patients died (n=2) or 
left practice (n=7) 
Left practice (n=1) 
Patients died (n=1), 
left practice (n=2), 
requested exclusion 
from research (n=1)  
Training received, N=15 
Alerts added to patient records, 
N=14 (n=422) 
 
Patients removed from at-
risk register, not given 
alert (n=35) 
1 yr follow up data available and 
included in ITT analysis, N=14 
(n=457, n=32 incomplete data 
due to death (n=3), leaving 
practice (n=29)) 
1 yr follow up data available and 
included in ITT analysis, N=15 
(n=454, n=27 incomplete data 
due to death (n=6), leaving 
practice (n=21)) 
No response, N=36; Declined, N 
= 27; Undecided, N=12; 
Ineligible, N=5 
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Figure 2: Identification and selection of patients for inclusion on asthma risk registers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This search had been piloted and optimised in an attempt to balance sensitivity and specificity at two different sized 
practices (9,000 and 16,900 patients) with differing software systems, at both identifying 9% of registered asthma 
patients as having severe asthma.  
†Due to poor coding of psychosocial problems in practice databases, electronic searches proved inadequate in 
identifying the majority of patients meeting criteria for being at-risk from their asthma at the pilot site[13] so use of 
local clinical knowledge was essential to ensure comprehensive identification of at-risk patients.
With justification and following discussion with the research team as necessary, other clinician-specified 
reason for patient not identified via above being considered at-risk from their asthma†. 
OR 
Age 5+ years 
AND 
Asthma diagnosis NOT chronic obstructive pulmonary disease 
Asthma admission in last 5 years 
OR 
A&E visit for asthma in last year 
OR 
Brittle asthma  
In the last 2 years, medications approximating to  
BTS Step 4-5 treatment, namely: 
 
1+ issue of high-dose inhaled steroids (100 mcg 
beclomethasone dipropionate equivalent for children aged 
5-11 yrs, 250 mcg for patients aged 12+ yrs) including 
combination products  
AND 
1+ issue of a long-acting beta-agonist OR 
leukotreine receptor antagonist OR 
adverse reaction to a long-acting beta-agonist 
AND 
1+ issue of prednisolone 5mg OR nebuliser 
AND SEVERE ASTHMA INDICATED BY: 
OR 
Clinician opinion, with reference to patient notes as necessary, regarding presence of one or more 
of: 
 
 adherence problems 
 failure to attend primary or secondary care appointments or self-discharge from hospital 
 psychosis, depression, self-harm or other psychiatric illness  
 alcohol or drug abuse 
 major tranquiliser use 
 smoking 
 obesity 
 denial 
 learning difficulties 
 employment problems 
 income problems 
 social isolation 
 childhood abuse 
 severe domestic, marital or legal stress 
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Intervention 
 
The practice-level intervention comprised:  
 
(1) Addition of electronic alerts visible to all staff to the computerised records of identified at-risk 
patients to flag their at-risk status at each contact. Wording was customised by the practice (e.g. 
“Asthma risk, prioritise care”; “ARRISA: vulnerable asthmatic”) and the appearance and visibility 
of alerts varied across different software (e.g. pop-ups requiring active clearance; yellow post-it 
style notes remaining on screen).  
 
(2) A 1-hour practice-based training session (Panel 1) to support effective use of the alerts at which 
at least one representative from each staff group (GP, nurse, receptionist, manager/administrator, 
dispenser) was present. The GP and nurse from the pilot study practice[14] led the standardised 
training, which advised staff on how to engage with, and improve the routine and emergency 
management of, at-risk asthma patients using case examples to highlight potential actions for 
receptionists, clinicians and dispensary teams (Panel 1). Practices agreed an action plan for 
cascading information to absent staff, providing reminders for existing staff, and inducting new 
staff. Alerts were activated once dissemination was complete.  
 
Intervention practices had open access to the study team, were telephoned at 1, 3 and 6 months and 
received a newsletter an average of five months after activation of alerts to reinforce 
implementation and encourage ongoing training. An end-of-study questionnaire (online Table A) 
assessed staff views on the intervention.  
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Panel 1: Content of practice training sessions 
 
• Introductions 
• Background and rationale covering evidence on morbidity and mortality and British guideline 
recommendations in relation to at-risk asthma patients; findings from the pilot study; the need to identify 
and facilitate rapid access for these patients; and the practice nurse perspective (to enhance nurse 
engagement and allay commonly expressed anxieties about increased workload). 
• Study aims and design. 
• Interactive exploration of practice’s existing experience, knowledge, awareness and current good 
practice with respect to at-risk asthma patients (e.g. any known asthma deaths or example patients, 
associated risk factors, existing management strategies such as following up admissions/out-of-hours 
contacts, prescription monitoring) and areas for improvement, which were probed to tailor subsequent 
discussions and the information provided. 
• Case study-based discussion drawing from practice examples or three pre-prepared clinical cases 
highlighting issues and possible strategies for improved management for receptionists (e.g. making a 
good first contact to improve engagement, fast-tracking clinical contact), clinicians (e.g. being accessible, 
engaging and educating patients, and addressing psychosocial or other factors affecting asthma at every 
opportunity), and dispensary team (e.g. being aware of prescription review dates and adherence 
indicators) as relevant to attendees.  
• Discussion and agreement regarding practice-specific implementation covering: 
− Appearance and wording of the electronic alert, which the practice customised to ensure optimal 
recognition and application.  
− Proposed actions for different staff in response to the alerts.  
− Parallel use of written lists in reception for some small practices. 
− Agreement of a dissemination action plan, as necessary, for cascading information to all absent 
practice staff (who does, how done, use of reminders, informing new staff etc.). 
− The issue of disclosure to patients, which was left to the discretion of the practice after reviewing the 
study ethics approval and pilot study experiences. 
− Amendments to the register, including questions regarding the eligibility of specific patients and 
forms to complete for adding or removing patients during the study so that all patients considered for 
inclusion could be tracked.  
• Follow-up plans. 
• Summary and thanks. 
 
Specific details of agreed implementation at the practice, along with generic content, were summarised in 
handouts provided to all attendees.  
 
 
 11
Control practices 
 
Following identification of at-risk asthma patients, control practices continued usual care, 
comprising at least annual practice-based asthma reviews in nurse-led clinics, plus follow-up in 
secondary care outpatient clinics and emergency primary and secondary care for some patients as 
required.[1] 
 
Data collection and coding  
 
Anonymous patient-level data on primary care-based clinical events and medications were extracted 
electronically from practice-based computerised records using NHS MIQUEST[16] or practice-
specific software. Data on secondary care and out-of-hours service use were manually extracted 
from letters/reports in individual records. Baseline data were collected for the one-year period prior 
to, and follow-up data for the one-year period following, activation of alerts at intervention 
practices for each pair of practices randomised together. Data were imported/entered into an Access 
database. One of two researchers used all available information to code clinical events as associated 
with an exacerbation, otherwise respiratory-related or unrelated to asthma. Data were then 
processed to generate descriptive characteristics, outcomes, and resource use estimates. Validation 
of selected data with other sources (e.g. for ambulance use) did not highlight any missing data in 
practice records and coding of deaths and exacerbations were checked (see below). Since 
electronically-extracted data did not always allow complete or accurate differentiation between GP 
and nurse, or respiratory and non-respiratory primary care contacts, detailed data on such contacts 
for costing were manually extracted from records for a random sample of up to five patients per 
practice.  
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The primary outcome was the number of patients experiencing a moderate-severe exacerbation, 
defined as per contemporaneous studies[17] as those resulting in death (determined in a blinded 
review of records by two physicians), hospitalisation, accident and emergency (A&E) attendance, 
out-of-hours medical contact, or a course or boost in oral corticosteroids (prednisolone) for asthma. 
An algorithm was applied to automatically code two or more events occurring <14 days apart as a 
single exacerbation. Where there was uncertainty regarding use of prednisolone for maintenance 
treatment versus exacerbations (based on three or more prescriptions of >60 prednisolone tablets), 
or three or more events were each separated by <14 days, prescription and clinical data were 
manually reviewed by researchers blind to study group and a clinical opinion sought as necessary to 
determine the number of exacerbations represented. Exacerbation counts from a sub-sample of 50 
such complex cases were compared between the two researchers and a further 20 were checked by 
an independent clinician, with high levels of agreement shown (Kappa for both >0.71).  
 
Secondary outcomes were individual components comprising an exacerbation as above, outpatient 
attendances for asthma, primary care contacts, ‘did not attends’ (DNAs) at consultations, and 
asthma medications. Prescription data were processed to provide counts of inhalers/packs issued for 
medications, with combination products counted under both relevant categories and 
beclomethasone-equivalent daily doses calculated for inhaled corticosteroids. Asthma severity was 
described as the number of classes (0 to 9) of asthma medications prescribed in the baseline year, 
counting high- and low-dose inhaled corticosteroids separately. Smoking history, a Charlson co-
morbidity index score,[18] co-existing rhinitis, and socio-demographic characteristics were derived 
from baseline data, supplemented with follow-up data where this was missing. 
 
Statistical analyses 
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An effective sample size of 134 patients per group was initially calculated assuming Type I error 
0·05, Type II error 0·1, and an exacerbation rate of 50% in controls and 30% in the intervention 
group, based on pre- and post-intervention observations in the pilot study.[12] To adjust for 
clustering, a mean cluster size (number of at-risk asthma patients per practice) of 20 and an intra-
cluster correlation coefficient (ICC) of 0·05,[19] was assumed, yielding a sample size of 268 
patients per group. However, analyses of baseline exacerbation data from the initial 19 practices 
recruited indicated a mean cluster size of 36, and an ICC=0·068 which, with other previous 
assumptions, suggested randomising 453 patients (13 practices) per group to achieve the equivalent 
of the original sample size based on individual randomisation. 
 
Descriptive data were visually compared to identify any major baseline differences between groups, 
and covariates for inclusion in fully adjusted analyses were selected from a list of pre-specified 
prognostic variables. Adjustments were made for independent predictors of the primary 
outcome[20] identified via simple and multiple regression.  
 
Mixed-effect models were used to adjust for clustering of outcomes within practices[21] in 
producing effect sizes, 95% confidence intervals (CI) and p-values. Analyses were conducted with 
random effect for practice, adjusted for stratification (above/below-average IMD) alone 
(‘unadjusted’) and additionally adjusted for baseline values of the outcome and other selected 
covariates (‘adjusted’). Random-effects logistic models producing odds-ratios (ORs) were used for 
binary outcomes (n, %) since there was no difference in follow-up times between groups (p=0·458; 
Mann-Whitney test). Intra-cluster correlation coefficients (ICCs) were estimated in these models for 
the primary outcome and its components. Random-effects negative-binomial models, producing 
rate-ratios (RRs), taking into account each patient’s observation time, were used for outcomes 
experienced by the majority of patients where ORs exaggerate effects. Results for these were 
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described using median and inter-quartile range (IQR) rates (counts per year), since they were 
generally heavily positively skewed with extra-Poisson variation.  
 
The main analyses were undertaken on an intention-to-treat (ITT) basis including all at-risk patients 
identified pre-randomisation who were alive and registered with practices on the date alerts were 
activated at intervention practices. Additional analyses were conducted in a ‘pure’ sub-group of the 
ITT sample (analogous to ‘per protocol’) that excluded patients: 1) removed from registers by 
practices between randomisation and the start of follow-up, whose records therefore did not receive 
an alert, or 2) subsequently identified as having a COPD diagnosis recorded during their baseline 
year. To examine potential impacts of variations in the visibility of alerts and data extraction 
methods, another pre-specified, secondary ITT analysis tested the interaction between practice 
software-type (EMIS vs. non-EMIS) and the intervention. Analyses were performed using Stata 
(StataCorp. Stata Statistical Software: Release 11·1SE. College Station, TX, USA. 2009). Nominal 
significance level was 5% throughout; with no adjustments for multiple testing. 
 
Cost analyses 
 
Total respiratory- and non-respiratory-related costs were estimated from the viewpoint of the UK 
NHS with resource use valued at 2007-8 rates using unit costs from published[22-25] or local 
sources as applicable. Implementation costs (searching for and identifying patients, setting up alerts, 
delivering training, practice follow-up) for each practice were estimated using researcher records. 
Per-patient costs for the entire baseline and follow-up years were estimated and for patients joining 
practices during baseline or leaving during follow-up the average cost per day for items in the same 
period was applied to any time for which data were missing.  
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The mean change in annual NHS costs was estimated for control and intervention groups. 
Additionally, the (unadjusted) mean incremental cost was estimated by taking the difference 
between the mean change in costs across groups. Finally, to take account of clustering, a two-stage 
bootstrap procedure was used to estimate the adjusted incremental cost between groups.[26] 
 
 
RESULTS 
 
Thirty practices were recruited. One intervention practice was excluded after training due to a 
software change precluding activation of alerts. Twenty-nine practices therefore identified 911 at-
risk asthma patients with data available for analyses (Figure 1). Baseline characteristics (Table 1) 
were similar, except that at practice level intervention practices had larger and more deprived 
populations, and were less likely using EMIS software. There were some differences in patient-
level exacerbations and DNA rates, and in medications prescribed, especially nebulised 
bronchodilators. Adjustments were made for baseline differences in prognostic variables as 
indicated.  
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Table 1: Baseline practice and patient characteristics 
Data are N (%) and reported at patient-level unless otherwise indicated.  
 
 
Intervention 
group 
(N=14 practices, 
457 patients) 
Control  
group 
(N=15 practices, 
454 patients) 
All  
practices 
(N=29 practice, 
911 patients) 
Practice-level characteristics    
Median (IQR) practice list size* 
 
8368  
(4428) 
7892  
(5770) 
8002  
(4948) 
Median (IQR) Index of Multiple Deprivation 
score, where higher = more deprived† 
25·24  
(15·08) 
16·89  
(11·83) 
20·28  
(14·13) 
Practice software system: 
EMIS LV 
EMIS PCS 
VISION 
SystmOne 
Torex Synergy  
 
2 (14·3%) 
2 (14·3%) 
5 (35·7%) 
4 (28·6%) 
1 (7·1%) 
 
9 (60·0%) 
2 (13·3%) 
3 (20·0%) 
1 (6·7%) 
0 
 
11 (37·9%) 
4 (13·8%) 
8 (27·6%) 
5 (17·2%) 
1 (3·4%) 
Median (IQR) no. patients on asthma register* 
 
606·00 
(213·25) 
531·00 
(394·50) 
574·00 
(287·00) 
Median (IQR) no. severe asthma patients 
identified 
65·50  
(21·75) 
56·00  
(38·00) 
60·00  
(31·00) 
Median (IQR) no. at-risk asthma patients 
identified  
19.00  
(36.75) 
13.00  
(30.00) 
18.00  
(37.00) 
Patient demographic and clinical 
characteristics 
   
Female gender 
 
287  
(62·8%) 
271 
 (59·8%) 
558 
(61·3%) 
Mean (SD) age 
 
46·4  
(22·1) 
44·6 
(21·7) 
45·5 
(21·9) 
Aged <16 years 
 
51 
(11·2%) 
56 
(12·3%) 
107 
 (11·8%) 
Median (IQR) severity score based on no. 
classes of asthma medications prescribed (0-9) 
4 
(2) 
4 
(2) 
4 
(2) 
Charlson co-morbidity index score: 
0 
1-2 
3+ 
 
325 (71·1%) 
105 (23·0%) 
27 (5·9%) 
 
321 (70·7%) 
98 (21·6%) 
35 (7·7%) 
 
646 (70·9%) 
203 (22·3%) 
62 (6·8%) 
Smoking status:  
Never smoked 
Non-smoker 
Ex-smoker 
Smoker 
Missing data 
 
176 (38·5%) 
17 (3·7%) 
118 (25·8%) 
95 (20·8%) 
51 (11·2%) 
 
158 (34·8%) 
32 (7·1%) 
93 (20·5%) 
100 (22·0%) 
71 (15·6%) 
 
334 (36·7%) 
49 (5·4%) 
211 (23·2%) 
195 (21·4%) 
122 (13·3%) 
Exacerbation-related events    
Moderate-severe exacerbation in past year   
 
293  
(64·1%) 
266 
(58·6%) 
559 
(61·4%) 
Median (IQR) rate of moderate-severe 
exacerbations 
1  
(2) 
1  
(2) 
1 
(2) 
Hospitalisation for asthma exacerbation‡ 28 
(6·1%) 
32 
(7·1%) 
60 
(6·6%) 
A&E attendance for asthma exacerbation‡ 50  
(10·9%) 
49 
(10·8%) 
99 
(10·9%) 
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Intervention 
group 
(N=14 practices, 
457 patients) 
Control  
group 
(N=15 practices, 
454 patients) 
All  
practices 
(N=29 practice, 
911 patients) 
Out-of-hours contact for asthma exacerbation‡ 45 
(9·9%) 
36 
(7·9%) 
81 
(8·9%) 
Oral prednisolone course for asthma 
exacerbation‡ 
293 
(64·1%) 
272 
(59·9%) 
565 
(62·0%) 
Ambulance call for asthma exacerbation 19 
(4·2%) 
19 
(4·2%) 
38 
(4·2%) 
Nebulised short-acting β-agonist for asthma 
exacerbation 
46 
(10·1%) 
79 
(17·4%) 
125 
(13·7%) 
Other health care attendances    
Secondary care outpatient consultations for 
asthma  
92 
(20·1%) 
91  
(20·0%) 
183 
(20·1%) 
Median (IQR) rate of primary care 
consultations for any reason 
10 
(9) 
9 
(10) 
9 
(10) 
‘Did not attend’ (DNAs) at primary care 
consultation for any reason 
84 
(18·4%) 
109 
(24·1%) 
193 
(21·2%) 
Other asthma medications    
Median (IQR) rate of short-acting β-agonist 
inhalers prescribed 
7 
(9) 
8 
(11) 
7 
(11) 
Median (IQR) BDP-equivalent µg/day dose of 
inhaled corticosteroids prescribed 
723  
(986) 
657 
(986) 
685 
(986) 
Median (IQR) rate of long-acting β-agonist 
inhalers prescribed 
8 
(7) 
6 
(9) 
7 
(8) 
Leukotreine receptor antagonists prescribed 101 
(22·1%) 
125 
(27·5%) 
226 
(24·8%) 
Theophyllines prescribed 27 
(5·9%) 
42 
(9·3%) 
69 
(7·6%) 
*Source:  QOF0708_Pracs_Prevalence.xls spreadsheet via http://www.ic.nhs.uk/statistics-and-data-collections/audits-
and-performance/the-quality-and-outcomes-framework/the-quality-and-outcomes-framework-2007-08  
†Source: Norfolk Deprivation data 2007 provided by NHS Norfolk, see: http://www.norfolkinsight.org.uk/deprivation 
for further information. 
‡ Event included in count of exacerbations (see methods for full definition). 
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Mean observation periods (Table 2) and losses to follow-up through patients dying or leaving 
practices (Figure 1) were similar across groups (93·0% intervention, 94·7% control with complete 
data). Nine patients died during follow-up, six of these (including the only one deemed due to 
asthma) were in the control group.  
 
In unadjusted and fully adjusted ITT analyses, there was no significant difference between groups 
in the number of patients experiencing a moderate-severe exacerbation (primary outcome expressed 
as odds) during the follow-up year (Table 2) or in the rate of exacerbations per person per year 
(median (IQR) = 1 (2) for intervention, 0 (2) for control; RR (95% CI) = 1·21 (0·95; 1·55), p=0·13 
unadjusted; 1·16 (0·97; 1·38), p=0·11 adjusted). However, disaggregating this composite outcome, 
the intervention halved the odds of patients experiencing hospitalisation, non-significantly reduced 
the proportions using A&E and out-of-hours services and increased the odds of patients receiving 
pulse prednisolone. Significantly fewer intervention patients received nebulised β-agonists and they 
were prescribed significantly more long-acting beta-agonists (LABAs) (Table 2). Findings were 
similar when analyses were confined to the “pure group” excluding intervention group patients who 
did not receive alerts (n=35) or were found to have a COPD diagnosis (n=24) (online Table B). 
Similar patterns and sizes of effects were also observed when rates of events were analysed to take 
account of truncated follow-up for some patients. Software-type was not related to the primary 
outcome and there were no significant interactions of software-type with the intervention for the 
primary outcome (OR (95% CI) for unadjusted interaction = 1·17 (0·57; 2·38); p=0·7). The ICC for 
the primary outcome, conditional on stratification, was 0·013 (95% CI 0·002; 0·087). ICCs for 
components of this outcome are shown in online Table C. 
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Table 2: Primary and secondary outcomes at one year: results from intention-to-treat analyses 
 
Data are at patient-level, showing N (%) experiencing event per year and odds ratios (OR) unless otherwise indicated.  
 
 
Intervention 
(N=14 pracs, 
n=457 px) 
Control  
(N=15 pracs, 
n=454 px) 
Unadjusted 
OR† (95% 
CI) unless 
indicated 
p Adjusted  
OR‡ (95% 
CI) unless 
indicated 
p 
Mean (range) cluster size, comprising number 
of high risk patients on register per practice 
32·6 
(3; 82) 
30·3 
(4; 90) 
    
Mean (SD) days per person post-intervention 
observation time 
352 
(54) 
358 
(36) 
    
Primary outcome 
Moderate-severe asthma exacerbation 245 
(53·6%) 
211 
(46·5%) 
1·30 
(0·93; 1·80) 
 
0·120 
1·27 
(0·95; 1·70) 
 
0·105 
Secondary outcomes: exacerbation-related events 
Hospitalisation for asthma exacerbation* 15 
(3·3%) 
29 
(6·4%) 
0·50 
(0·26; 0·94) 
 
0·031 
0·51 
(0·26; 1·00) 
 
0·051 
A&E attendance for asthma exacerbation* 29 
(6·4%) 
37 
(8·2%) 
0·74 
(0·42; 1·31) 
 
0·303 
0·70 
(0·37; 1·34) 
 
0·284 
Out-of-hours contact for asthma exacerbation* 26 
(5·7%) 
32 
(7·1%) 
0·79 
(0·45; 1·37) 
 
0·396 
0·75 
(0·41; 1·37) 
 
0·350 
Oral prednisolone course for asthma 
exacerbation* 
247 
(54·1%) 
213 
(46·9%) 
1·31 
(0·92; 1·85) 
 
0·136 
1·28 
(0·95; 1·73) 
 
0·112 
Ambulance call for asthma exacerbation 13 
(2·8%) 
12 
(2·6%) 
1·03 
(0·42; 2·51) 
 
0·950 
1·02 
(0·45; 2·35) 
 
0·954 
Nebulised short-acting β-agonist for asthma 
exacerbation 
36 
(7·9%) 
63 
(13·9%) 
0·51 
(0·29; 0·88) 
 
0·016 
0·61 
(0·36; 1·02) 
 
0·061 
Secondary outcomes: other health care attendances      
Secondary care outpatient consultations for 
asthma  
81 
(17·7%) 
71 
(15·6%) 
1·14  
(0·76; 1·70) 
 
0·532 
1·27 
(0·82; 1·98) 
 
0·283 
Median (IQR) rate of primary care 
consultations for any reason 
9 
(11) 
8 
(11) 
1·09§ 
(0·95; 1·26) 
 
0·234 
1·06¶ 
(0·97; 1·16) 
 
0·190 
‘Did not attend’ (DNAs) at primary care 
consultation for any reason 
82 
(17·9%) 
105 
(23·1%) 
0·64 
(0·29; 1·42) 
 
0·270 
0·73 
(0·35; 1·52) 
 
0·396 
Secondary outcomes: other asthma medications 
Median (IQR) rate of short-acting β-agonist 
inhalers prescribed 
6 
(10) 
7 
(12) 
1·03§ 
(0·89; 1·19) 
 
0·666 
1·03¶ 
(0·91; 1·17) 
 
0·600 
Median (IQR) BDP-equivalent µg/day dose of 
inhaled corticosteroids prescribed 
658 
(1036) 
658 
(1036) 
1·10§ 
(0·97; 1·25) 
 
0·152 
1·07¶ 
(0·96; 1·18) 
 
0·223 
Median (IQR) rate of long-acting β-agonist 
inhalers prescribed 
8 
(9) 
6 
(9) 
1·24§ 
(1·08; 1·43) 
 
0·002 
1·08¶ 
(0·99; 1·17) 
 
0·085 
Leukotreine receptor antagonists prescribed 111 
(24·3%) 
131 
(28·9%) 
0·85 
(0·55; 1·31) 
 
0·459 
0·96 
(0·49; 1·86) 
 
0·895 
Theophyllines prescribed 23 
(5·0%) 
40 
(8·8%) 
0·56 
(0·29; 1·07) 
 
0·079 
0·53 
(0·21; 1·34) 
 
0·179 
*Event included in count of exacerbations (see methods for full definition). 
†Odds ratio estimated using ‘univariate’ analysis of proportions in random-effects logistic regression model, adjusted for clustering 
and stratification only 
‡Odds ratio estimated using multivariable analysis of proportions in random-effects logistic regression model, adjusted for 
clustering and stratification plus baseline values of outcome variable, exacerbation count, age (continuous), asthma severity (no. 
classes of meds), Charlson co-morbidity index (in 3 categories), and rhinitis.  
§Rate ratio estimated using ‘univariate’ analysis of counts in random-effects negative binomial regression model, adjusted for 
clustering and stratification only. 
¶Rate ratio estimated using multivariable analysis of counts in random-effects negative binomial regression model adjusted for 
clustering and stratification plus baseline values of outcome variable, exacerbations count, age (continuous), asthma severity 
(#classes of meds), Charlson co-morbidity index (in 3 categories), and rhinitis. 
 20
Costs 
 
The mean per practice intervention implementation cost was £1687·40, comprising set-up 
(£414·24), training (£1211·17) and follow-up (£62·00), equating to an average of £51·69 per 
patient.  
 
When proportions of nurse (41·2%, n=1070), GP (58·8%, n=1524), respiratory-related (34·2%, 
n=887) and non-respiratory-related visits (65·8%, n= 1707) obtained from manual extraction of data 
on 2594 visits from a sub-sample of 139 patients were applied to all primary care contacts, mean 
primary care costs were estimated to be similar in both groups during baseline and follow-up (Table 
3). Estimated medication costs were also similar. Out-of-hours costs tended to be lower during 
follow-up for both groups, whereas secondary care costs tended to be higher (mean change 
estimates favoured the intervention group for both). Overall, there was an increase in costs for both 
groups but the increase was larger for the control group resulting in an overall (unadjusted) 
incremental cost of –£88·91 per patient (Table 3) i.e. mean NHS costs were lower in intervention 
compared to control practices despite the additional £52 cost of implementing the intervention. 
When clustering was accounted for the adjusted mean per patient cost was estimated as –£138·21 
(95% CI –£1248·36 to £910·58, p=0·837).  
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Table 3: Per patient mean annual levels of resource use and associated estimated costs in each arm and unadjusted incremental costs 
Item Group Respiratory related Non-respiratory related Overall 
  Baseline Follow-up Change Incremental cost Baseline Follow-up Change Incremental cost Baseline Follow-up Change Incremental cost 
Intervention 
cost 
Intervention 
Control 
– 
– 
£51·69 
– 
£51·69 
– 
£51·69 – 
– 
– 
– 
– 
– 
 – 
– 
£51·69 
– 
£51·69 
– 
£51·69 
Primary care              
No. contacts 
 
Intervention 
Control 
4·06 
3·98 
3·92 
3·80 
–0·14 
–0·18 
 7·83 
7·68 
7·56 
7·33 
–0·26 
–0·35 
 11·88 
11·66 
11·48 
11·12 
–0·40 
–0·54 
 
Cost 
 
Intervention 
Control 
£104·39 
£102·42 
£100·88 
£97·70 
–£3·51 
–£4·72 
£1·21 £200·89 
£197·11 
£194·13 
£188·02 
–£6·76 
–£9·09 
£2·33 £305·28 
£299·54 
£295·01 
£285·73 
–£10·27 
–£13·81 
£3·54 
Secondary care              
No. contacts 
 
Intervention 
Control 
0·86 
0·89 
0·63 
0·67 
–0·23 
–0·22 
 2·65 
2·49 
2·56 
2·34 
–0·09 
–0·15 
 3·51 
3·38 
3·19 
3·00 
–0·32 
–0·37 
 
Cost 
 
Intervention 
Control 
£250·68 
£322·29 
£274·97 
£342·99 
£24·29 
£20·70 
£3·60 £673·13 
£700·84 
£684·98 
£834·21 
£11·85 
£133·37 
–£121·52 £923·81 
£1023·13 
£959·95 
£1177·20 
£36·14 
£154·07 
–£117·93 
Out of hours              
No. contacts 
 
Intervention 
Control 
0·26 
0·27 
0·16 
0·28 
–0·09 
0·01 
 0·26 
0·54 
0·17 
0·39 
–0·09 
–0·15 
 0·52 
0·81 
0·34 
0·67 
–0·18 
–0·14 
 
Cost 
 
Intervention 
Control 
£10·83 
£11·09 
£7·49 
£11·46 
–£3·34 
£0·37 
–£3·71 £10·46 
£20·58 
£6·28 
£14·07 
–£4·18 
–£6·52 
£2·34 £21·29 
£31·67 
£13·76 
£25·52 
–£7·52 
–£6·15 
–£1·37 
Medication              
No. prescriptions Intervention 
Control 
25·67 
19·76 
17·82 
18·75 
–7·85 
–1·00 
 38·59 
39·93 
37·74 
42·68 
–0·85 
2·75 
 64·26 
59·68 
55·56 
61·43 
–8·70 
1·75 
 
Cost 
 
Intervention 
Control 
£488·62 
£489·25 
£488·49 
£479·88 
–£0·13 
–£9·37 
£9·24 £390·82 
£377·09 
£381·14 
£401·48 
–£9·68 
£24·40 
–£34·08 £879·45 
£866·33 
£869·64 
£881·36 
–£9·81 
£15·03 
–£24·84 
Total cost 
 
Intervention 
Control 
£854·52 
£925·06 
£923·52 
£932·03 
£69·00 
£6·97 
£62·03 £1,275·31 
£1,295·62 
£1,266·53 
£1,437·79 
–£8·77 
£142·17 
–£150·94 £2129·83 
£2220·68 
£2190·06 
£2369·81 
£60·23 
£149·14 
–£88·91 
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End of study questionnaire 
 
Eleven of 14 intervention practices returned questionnaires, with at least two categories of staff 
(GP, nurse, receptionist) responding from each. Results (online Table A) suggest almost all staff felt 
the alerts were useful to at least some extent and would continue using them, most felt they did not 
increase workload and negative comments were received from only one practice. Despite this, 70% 
felt that the alerts had altered their management only slightly or not at all.  
 
 
DISCUSSION 
 
Summary of findings 
 
Establishing electronic alerts linked to asthma risk registers and providing training on their use to 
facilitate access and provision of opportunistic asthma care did not reduce a composite indicator of 
moderate-severe exacerbations using contemporaneous[17] or current definitions.[27] However, 
these definitions include an indicator of good practice (prescription of prednisolone for 
exacerbations) alongside adverse outcomes (A&E attendances, hospitalisations), and potentially 
mask the benefits of this type of intervention, particularly for patients with severe asthma 
experiencing frequent exacerbations. Considering this, we showed reductions in hospitalisations and 
nebulised β-agonists prescribed; and increases in prescription of preventative therapies as per 
guidelines i.e. oral prednisolone for exacerbations and LABAs for patients already on inhaled 
corticosteroids. There were also non-significant reductions in A&E attendances and DNAs for 
routine appointments. Although numerous endpoints were examined with only a few secondary 
outcomes showing consistently significant findings, the overall pattern of results suggest that use of 
asthma risk registers improved patient management (e.g. more appropriate prescribing) and patient 
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outcomes (reduced crisis events, including hospitalisations). Furthermore, the intervention was 
generally well-accepted and did not increase costs. 
 
Interpretation in light of previous research 
 
Hospitalisation represents a significant event in the lives of asthma patients, is an indicator of 
severity, predicts re-admission and death[28,29] and constitutes a major expense.[4,6] Identifying 
methods for reducing hospitalisations is therefore paramount to patients, healthcare providers and 
funders. Although small numbers (5%) experienced hospitalisations, our intervention reduced 
admissions by a similar magnitude to that observed across more intensive asthma education 
programmes,[10] including amongst children [30] or adults attending A&E for asthma[32]. Poor 
adherence, including failing to attend appointments, is common amongst at-risk patients[7,9] and 
notably only 20% of our sample attended secondary care asthma clinics, highlighting the 
importance of primary care intervention.  
 
Asthma risk registers represent a complex intervention and any beneficial effects may stem from 
impacts of the alerts and training on enhanced access, improved routine and emergency care and/or 
increased opportunistic asthma management. However, feedback from staff suggests that despite 
recognising the utility of the registers, they perceived few impacts on their management, including 
the ability of receptionists to prioritise appointments. The mechanisms of any effects therefore 
remain unexplored, though they were not dependent on practice software-type and nature of the 
alerts and likely stem from a combination of the training and electronic flagging of at-risk patients. 
Patient education is considered essential to asthma management, but health professional education 
has been less well-investigated.[32] However, in the more intensive ELECTRA study 
intervention,[33] review of at-risk asthma patients in a nurse-led clinic, and educational outreach 
and promotion of guidelines for at-risk asthma to primary care clinicians delayed time to first 
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presentation and reduced the proportion of at-risk patients attending with exacerbations (OR 0·62, 
CI 0·83;1·01). 
 
Strengths and limitations 
 
Variability in the characteristics of practices and their implementation of the intervention may 
explain the wide confidence intervals around estimates of effects and costs, but also increases 
generalisability of the findings. Use of anonymous, routinely available data to assess outcomes 
ensures applicability of findings to all at-risk asthma patients. However, it failed to provide a more 
patient-focussed outcome suitable for use in a full cost-effectiveness analysis and there were some 
difficulties with data extraction. Practice software did not permit accurate or comprehensive 
determination of whether primary care attendances were nurse or GP-led, or related to asthma. 
Consequently, data were manually extracted for a sub-sample to inform the primary care resource 
utilisation and costs, though this represented a small proportion of total costs. Incomplete coding of 
hospitalisations and A&E attendances in practice records also meant there was potential for some 
exacerbations treated only in hospital to be missed. However, 86% of all exacerbations identified 
were associated with a prescription of prednisolone in primary care, which is comprehensively 
coded, so numbers are likely to be small and to have had minimal impact on results since control 
and intervention groups would have been similarly affected. We also undertook manual review of 
clinical information and selected blind checks for the 15% of patients for whom the number of 
exacerbations was uncertain, manual review of consultation data for up to five patients per practice, 
and validation with other sources where possible to maximise the accuracy and completeness of our 
data. 
 
Conclusions and implications 
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Our findings suggest potential clinical benefit for a group at serious risk from their asthma, who 
utilise a high proportion of costly healthcare resources and, as a result of psychosocial problems, 
often have difficulty engaging with healthcare services and interventions. The use of registers for 
these patients may reduce hospitalisations and improve aspects of their care, such as prescribing 
practice, with no increase in perceived staff workload or costs. This study does not provide 
conclusive evidence to support the suggestion in current British asthma guidelines[1] that asthma 
risk registers may be helpful. However, it informs how they can be implemented in practice and 
provides a basis for further research studies.  
 
 
ACKNOWLEDGEMENTS 
 
With thanks to Asthma UK for funding, all the practices and their staff involved, patient 
representatives on the Project Management Group Penny Vicary and Margaret Kent, Drs Shuaib 
Nasser, Richard Gilbert, and John Battersby who served on the Independent Trial Steering 
Committee, and Database Manager Tony Dyer, Computer Science student Ricardo Ramirez-
Gonzalez and Researcher Adam Martin for database development and assistance with database 
programming and costing respectively.  
 
COPYRIGHT 
 
The corresponding Author has the right to grant on behalf of all authors and does grant on behalf of 
all authors, an exclusive licence on a worldwide basis to the BMJ Group and co-owners or 
contracting owning societies (where published by the BMG Group on their behalf), and its 
Licensees to permit this article (if accepted) to be published in Thorax and any other BMJ Group 
products and to exploit all subsidiary rights, as set out in our licence. 
 26
 
COMPETING INTERESTS 
 
All researchers in the study were independent of the funding body. All authors have completed the 
Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from 
the corresponding author) and declare: no support from any organisation for the submitted work; no 
financial relationships with any organisations that might have an interest in the submitted work in 
the previous three years; no other relationships or activities that could appear to have influenced the 
submitted work. 
 
AUTHORS’ CONTRIBUTION 
 
All authors had full access to all of the data (including statistical reports and tables) in the study and 
can take responsibility for the integrity of the data and the accuracy of the data analysis. 
Jane R Smith was a joint principal investigator. She was involved in the pilot study, contributed to 
the original protocol design, led the funding application and co-ordinated the overall running of the 
project. She oversaw the outcome and cost analyses, contributed to interpretation of findings and 
drafted and edited the paper.  
Michael J Noble led the pilot study, contributed to protocol design, led the design and delivery of 
the intervention, advised on data collection and coding, contributed to interpretation of findings, 
drafted sections on the intervention in the methods and commented on drafts. 
Stanley Musgrave was responsible for day-to-day project management, undertook practice 
recruitment and liaison, was involved in data collection, coding and management, drafted sections 
on recruitment, data collection and coding in the methods, contributed to interpretation of findings 
and commented on drafts. 
 27
Jamie Murdoch undertook practice recruitment and liaison, was involved in data collection, coding 
and management, drafted sections on data collection and coding in the methods, and commented on 
drafts. 
Gill M Price oversaw randomisation, planned and conducted outcomes analyses, contributed to 
interpretation of findings, drafted sections/tables on the outcomes analyses in the methods and 
results, and commented on drafts  
Garry Barton conducted and interpreted the cost analyses, drafted sections on costs in the methods 
and results, and commented on drafts. 
Jennifer Windley was involved in the pilot study, contributed to intervention design and delivery, 
and commented on drafts. 
Richard Holland contributed to protocol design and the funding application, advised on analyses, 
and commented on drafts. 
Brian DW Harrison contributed to protocol design, advised on data coding, contributed to 
interpretation of findings, and commented on drafts. 
Amanda Howe commented on the funding application, advised on intervention design and delivery, 
and commented on drafts. 
David Price advised on data collection, coding and management, and commented on drafts. 
Ian Harvey commented on protocol design, advised on analyses, and commented on drafts. 
Andrew M Wilson was a joint principal investigator. He contributed to the original protocol design 
and funding application, and gained ethical and regulatory approvals. He chaired the trial steering 
group meetings, was involved with the analysis plan, commented on drafts and edited the final 
paper.  
 
CONFLICTS OF INTEREST 
 
None of the authors have a conflict of interest. 
 28
 
ROLE OF THE FUNDING SOURCE AND SPONSOR 
 
This study was funded by Asthma UK (Project no. 06/047). Neither the funder nor sponsor had a 
role in the design, data collection, analysis, interpretation, writing up, or decision to submit for 
publicatio 
n, responsibility for which rested solely with the authors.  
 
REGISTRATION AND APPROVAL 
 
ISRCTN trial register number 36918958.  
Approved by Norfolk Research Ethics Committee (reference number 06/Q0101/200).  
 
REFERENCES  
 
1. British Thoracic Society & Scottish Intercollegiate Guideline Network. British guideline on the 
management of asthma. Thorax 2003;58(Suppl 1):i1-94.  
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of 
the GINA Dissemination Committee report. Allergy 2004;59:469-78. 
3. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity 
and control of asthma in children and adults: the global asthma insights and reality surveys. J 
Allergy Clin Immunol 2004;114:40-7. 
4. Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J Allergy 
Clin Immunol 2011;127:145-52. 
5. Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and 
costs associated with an asthma attack. Thorax 2000;55:19-24. 
6. Vervloet D, Williams AE, Lloyd A, Clark TJH. Costs of managing asthma as defined by a 
 29
dervied Asthma Control Test (TM) score in seven European countries. Eur Respir Rev 
2006;15:17-23. 
7. Sturdy PM, Victor CR, Anderson HR, Bland JM, Butland BK, Harrison BD, et al. 
Psychological, social and health behaviour risk factors for deaths certified as asthma: a national 
case-control study. Thorax 2002;57:1034-9. 
8. Wainwright NW, Surtees PG, Wareham NJ, Harrison BD. Psychosocial factors and incident 
asthma hospital admissions in the EPIC-Norfolk cohort study. Allergy 2007;62:554-60. 
9. Yoon R, McKenzie DK, Miles DA, Bauman A. Characteristics of attenders and non-attenders 
at an asthma education programme. Thorax 1991;46:886-90. 
10. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, et al. Self-
management education and regular practitioner review for adults with asthma. Cochrane 
Database Syst Rev 2002; Issue 3: CD001117. 
11. Smith JR, Mugford M, Holland R, Noble MJ, Harrison BD. Psycho-educational interventions 
for adults with severe or difficult asthma: a systematic review. J Asthma 2007;44:219-41. 
12. Sturdy PM, Butland BK, Anderson HR, Ayres JG, Bland JM, Harrison BD, et al. Deaths 
certified as asthma and use of medical services: a national case-control study. Thorax 
2005;60:909-15 
13. Noble MJ, Smith JR, Windley J. A controlled retrospective pilot study of an 'at-risk asthma 
register' in primary care. Prim Care Respir J 2006;15:116-24. 
14. NHS Employers Quality and Outcomes Framework. 
http://www.nhsemployers.org/PayAndContracts/GeneralMedicalServicesContract/QOF/Pages/
QualityOutcomesFramework.aspx (accessed Apr 4, 2011). 
15. Communities and local government. The English indices of deprivation report 2007. 
http://www.communities.gov.uk/publications/communities/indiciesdeprivation07 (accessed 
Apr 4, 2011). 
 30
16. PRIMIS+ Morbidity Information Query and Export Syntax (MIQUEST) software. 
http://www.primis.nhs.uk/index.php/services/information-services/miquest (accessed Apr 4, 
2011). 
17. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, et al. 
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET 
International Study Group. Am J Respir Crit Care Med 1999;160:594-9. 
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-
83. 
19. Campbell MK, Mollison J, Grimshaw JM. Cluster trials in implementation research: estimation 
of intracluster correlation coefficients and sample size. Stat Med 2001;20:391-9. 
20. Altman DG, Dore CJ. Baseline comparisons in randomized clinical trials. Stat Med 
1991;10:797-9. 
21. Donner A, Klar N. Design and analysis of cluster randomization trials in health research. 
London: Arnold; 2000. 
22.  Curtis L. Unit costs of health and social care 2008. Canterbury: University of Kent Personal 
Social Services Research Unit, 2008. 
23. Department of Health. National Schedule of Reference Costs 2007-08. London: Department of 
Health, 2009. 
24. British Medical Association / Royal Pharmaceutical Society of Great Britain. British National 
Formulary (BNF) 55. London: Pharmaceutical Press, March 2008. 
25. The NHS Information Centre for Health and Social Care. Prescription Cost Analysis: England 
2008. http://www.ic.nhs.uk/statistics-and-data-collections/primary-
care/prescriptions/prescription-cost-analysis-2008 (Accessed Apr 4, 2011). 
26. Bachmann MO, Fairall L, Clark A, Mugford M. Methods for analyzing cost effectiveness data 
from cluster randomized trials. Cost Eff Resour Alloc 2007;5:12. 
 31
27.  Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official 
American Thoracic Society/European Respiratory Society statement: asthma control and 
exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J 
Respir Crit Care Med 2009;180:59-99. 
28. Crane J, Pearce N, Burgess C, Woodman K, Robson B, Beasley R. Markers of risk of asthma 
death or readmission in the 12 months following a hospital admission for asthma. Int J 
Epidemiol 1992;21:737-44. 
29. Mitchell EA, Bland JM, Thompson JM. Risk factors for readmission to hospital for asthma in 
childhood. Thorax 1994;49:33-6. 
30. Boyd M, Lasserson TJ, McKean MC, Gibson PG, Ducharme FM, Haby M. Interventions for 
educating children who are at risk of asthma-related emergency department attendance. 
Cochrane Database Syst Rev 2009;Issue 2:CD001290. 
31.  Tapp S, Lasserson TJ, Rowe B. Education interventions for adults who attend the emergency 
room for acute asthma. Cochrane Database Syst Rev 2007;CD003000 
32. Lemmens KM, Nieboer AP, Huijsman R. A systematic review of integrated use of disease-
management interventions in asthma and COPD. Respir Med 2009;103:670-91. 
33. Griffiths C, Foster G, Barnes N, Eldridge S, Tate H, Begum S, et al. Specialist nurse 
intervention to reduce unscheduled asthma care in a deprived multiethnic area: the east London 
randomised controlled trial for high risk asthma (ELECTRA). BMJ 2004;328:144. 
